- Home
- SILC vs SKYE Comparison
SILC vs SKYE Comparison
Compare SILC & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILC
- SKYE
- Stock Information
- Founded
- SILC 1987
- SKYE 2012
- Country
- SILC Israel
- SKYE United States
- Employees
- SILC N/A
- SKYE N/A
- Industry
- SILC Computer Manufacturing
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- SILC Technology
- SKYE Health Care
- Exchange
- SILC Nasdaq
- SKYE Nasdaq
- Market Cap
- SILC 84.7M
- SKYE 80.7M
- IPO Year
- SILC 1994
- SKYE N/A
- Fundamental
- Price
- SILC $13.74
- SKYE $1.82
- Analyst Decision
- SILC Hold
- SKYE Buy
- Analyst Count
- SILC 2
- SKYE 6
- Target Price
- SILC N/A
- SKYE $16.60
- AVG Volume (30 Days)
- SILC 20.3K
- SKYE 1.7M
- Earning Date
- SILC 04-28-2025
- SKYE 05-09-2025
- Dividend Yield
- SILC N/A
- SKYE N/A
- EPS Growth
- SILC N/A
- SKYE N/A
- EPS
- SILC N/A
- SKYE N/A
- Revenue
- SILC $58,114,000.00
- SKYE N/A
- Revenue This Year
- SILC $6.22
- SKYE N/A
- Revenue Next Year
- SILC $19.10
- SKYE N/A
- P/E Ratio
- SILC N/A
- SKYE N/A
- Revenue Growth
- SILC N/A
- SKYE N/A
- 52 Week Low
- SILC $11.35
- SKYE $1.14
- 52 Week High
- SILC $18.24
- SKYE $13.51
- Technical
- Relative Strength Index (RSI)
- SILC 45.91
- SKYE 51.69
- Support Level
- SILC $12.66
- SKYE $1.36
- Resistance Level
- SILC $14.14
- SKYE $3.73
- Average True Range (ATR)
- SILC 0.62
- SKYE 0.35
- MACD
- SILC 0.12
- SKYE 0.09
- Stochastic Oscillator
- SILC 76.47
- SKYE 26.29
About SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters; Edge Networking Solutions; FPGA Based Cards; x86 Open Appliances Bypass Switches and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.